1201790-19-3

Upstream product

• 116861-31-5 tert-butyl N-(3-chloropropyl)carbamate 
• 269409-70-3 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol 
• 76-09-5 2,3-dimethyl-2,3-butane diol 
• 71597-85-8 (p-hydroxyphenyl)boronic acid 
• 34619-03-9 tert-butyldicarbonate 
• 83948-53-2 3-bromopropylamine tert-butylcarbamate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 73183-34-3 bis(pinacol)diborane 
• 106-41-2 4-bromo-phenol 

Downstream Products

• 1417520-26-3 C₃₇H₄₅N₃O₄ 
• 1620955-45-4 C₂₉H₃₁N₅O₄ 
• 1620955-46-5 2-(4'-(3-aminopropoxy)-[1,1'-biphenyl]-4-yl)-1,6-naphthyridine-4-carbohydrazide hydrochloride 
• 1620955-44-3 C₃₀H₃₁N₃O₅ 

Relevant academic research and scientific papers

Fluorescence opening type diarylethene fluorescent probe, and preparation method and application thereof

The invention provides a fluorescence opening type diarylethene fluorescent probe, and a preparation method and application thereof. The fluorescence opening type diarylethene fluorescent probe has a structure as shown in a formula I, the probe is compose

HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE

This invention relates to novel compounds and pharmaceutical compositions comprising. Compounds of the invention useful as modulators of Rho-associated protein kinase (ROCK), for example ROCK1 and/or ROCK2 inhibitors. Methods of treatment employing the compounds are also contemplated by the present invention. The compounds of the invention are useful in treating ROCK mediated diseases.

IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS

The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which is useful in the treatment of a tumor through its ROS1 kinase enzyme activity inhibitory effect and NTRK kinase enzyme inhibitory effect. The present invention provides a compound having an imidazo[1,2-b]pyridazine structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R1, G, T, Y1, Y2, Y3, and Y4 are as defined herein.

IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS

The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which is useful in the treatment of a tumor through its ROS1 kinase enzyme activity inhibitory effect and NTRK kinase enzyme inhibitory effect. The present invention provides a compound having an imidazo[1,2-b]pyridazine structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R1, G, T, Y1, Y2, Y3, and Y4 are as defined herein.

METALLOENZYME INHIBITOR COMPOUNDS

The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

Malachite green derivative-functionalized single nanochannel: Light-and-pH dual-driven ionic gating

A highly efficient and perfectly reversible ionic gate that can be activated by pH or UV light is demonstrated. Switching between the OFF state and the ON state is mainly dependent on the surface charge transition brought about by a malachite green derivative attached to the interior surface of an ion track-etched conical nanochannel, which makes it suitable for confined spaces. Applications in electronics, actuators, and biosensors can be foreseen.

AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME

The invention relates to novel azacarbonlines having formula (I), wherein: R3, R4 represent independently H; hal; CF3; substituted oxy, optionally substituted alkoxy; optionally substituted amino; substituted carbonyl; optionally substituted carboxyl; optionally substituted amide; sulphur, such as optionally substituted sulphones, sulphoxides or sulphides; linear, branched or cyclic C1-C10 alkyl optionally comprising an optionally substituted heteroatom; optionally substituted linear, branched or cyclic C2-C7 alkenyl; optionally substituted linear or branched C2-C6 alkynyl; optionally substituted aryl or heteroaryl; of which may be optionally substituted; in the form of a base or an acid addition salt. The invention also relates to the use of same in therapeutics for the treatment of cancer and to synthesis methods.